BioNTech's $1 Billion Buyback Can't Mask the Pain of 1,860 Job Cuts

The market seldom likes mixed signals. On Monday, BioNTech stock slid 5.3 percent as investors digested a restructuring plan that trims nearly 1,900 jobs, shuts multiple production sites, and yet still leaves room for a $1 billion share repurchase program. The move underscores the tightrope the Mainz-based biotech is walking as it pivots from a pandemic windfall to a future built on cancer therapies.

The buyback, authorised in early May and running through May 2027, covers American Depositary Shares and will be funded from existing cash reserves. BioNTech ended the first quarter with roughly €16.8 billion in liquid assets and securities. The primary use of the repurchased shares is to meet stock-based compensation obligations — not to signal a cheap valuation. But the timing has raised eyebrows: why buy back stock while slashing headcount and shuttering factories?

The answer lies in the company's strategic overhaul. BioNTech is cutting around 1,860 roles and plans to close sites in Marburg, Tübingen, Wiesbaden, Idar-Oberstein and Singapore. The goal is to save an annual €500 million, with a long-term target of nearly $585 million in cost reductions by 2029. The restructuring reflects the collapse of COVID-19 vaccine revenue and a full-scale shift toward oncology, where BioNTech aims to become a leader in personalised cancer therapies.

Should investors sell immediately? Or is it worth buying BioNTech?

That pivot is burning cash. In the first quarter of 2026, revenue fell to €118.1 million from €182.8 million a year earlier. The net loss swelled to €531.9 million, driven by €557.0 million in research and development spending. Management nevertheless reaffirmed full-year guidance of between €2.0 billion and €2.3 billion in revenue — a wide range that leaves room for uncertainty.

BioNTech's pipeline offers the real counterweight to the losses. Two candidates are generating the most attention. Pumitamig, an antibody developed with Bristol Myers Squibb, has five new pivotal studies underway targeting triple-negative breast cancer and non-small-cell lung cancer. Gotistobart, meanwhile, posted phase 3 data from the PRESERVE-003 trial showing a more than 50 percent reduction in the risk of death for certain lung cancer patients — though those results still need confirmation in further pivotal tests. The company expects to release seven late-stage data readouts from its immunomodulator and antibody-drug conjugate programmes this year.

A separate tailwind comes from Brussels. EU negotiators this week agreed on the "Critical Medicines Act," a legislative package designed to secure European supply chains for essential drugs. The law includes a "Buy European" principle for public procurement, faster approval pathways, and preferential access to EU funding for established manufacturers like BioNTech. Currently up to 90 percent of active pharmaceutical ingredients are sourced from Asia, and the act aims to reduce that dependency — a development that could benefit BioNTech's domestic production footprint even as it closes plants.

Analysts remain broadly bullish despite the operational turmoil. Thirteen analysts cover the stock, and all rate it a buy. Harry Gillis at Berenberg trimmed his price target to $140 but kept a buy recommendation, praising the company's cost discipline. The key catalyst, they say, is delivering a commercial cancer immunotherapy by the end of 2026 — a milestone that would trigger a fundamental revaluation. Until then, BioNTech's €16.8 billion cash pile provides the cushion to absorb losses while its factory closures fund the future.

Ad

BioNTech Stock: New Analysis - 12 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECHS | boerse | 69313172 |